8-K: Kiromic BioPharma Secures $2 Million in Funding Through Convertible Note

Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor to fund its operations.

Summary

• Kiromic BioPharma issued a 25% Senior Secured Convertible Promissory Note for $2 million to an accredited investor on May 1, 2024.
• The note bears interest at 25% per annum, increasing to 27% upon default, and matures on May 1, 2025.
• The note is convertible into common stock at an initial price of $2.50 per share, subject to a 19.99% beneficial ownership limitation.
• The note is secured by all of the company's fixtures, equipment, and intellectual property.
• The proceeds will be used for the development of CAR-T cell therapy and general corporate purposes.

Sentiment

Score: 4

Explanation: The high interest rate and secured nature of the debt indicate a challenging financial position for the company, despite the successful capital raise. The potential for equity dilution is also a concern.

Positives

• The company has successfully secured $2 million in funding.
• The note provides a potential source of equity through conversion.
• The company retains the option to prepay the note without penalty.

Negatives

• The interest rate on the note is very high at 25%, increasing to 27% upon default.
• The note is secured by the company's assets, which could be at risk in case of default.
• The conversion of the note is subject to a beneficial ownership limitation of 19.99%.

Risks

• Failure to make payments on the note could trigger an event of default, increasing the interest rate to 27%.
• The company's assets are pledged as collateral, which could be seized in case of default.
• The conversion of the note could dilute existing shareholders if the note is converted to equity.
• The company may need to raise additional capital in the future.

Future Outlook

The company intends to use the proceeds from the note for the continued development of its CAR-T cell therapy and for general corporate purposes.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

This financing is typical for a biotech company in the development stage, seeking capital to fund research and development. The use of a convertible note is a common method for raising funds, offering investors the potential for equity upside.

Comparison to Industry Standards

• The 25% interest rate on the note is significantly higher than typical bank loans, reflecting the higher risk associated with early-stage biotech companies.
• Convertible notes are a common financing tool for biotech companies, but the specific terms, such as the interest rate and conversion price, vary widely based on the company's risk profile and market conditions.
• The security interest in the company's assets is a standard practice for secured debt, providing the lender with some protection in case of default.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into equity.
• Employees may benefit from the continued funding of the company's operations.
• Creditors may be impacted by the senior secured nature of the note.

Next Steps

• The company will use the funds for the development of its CAR-T cell therapy and general corporate purposes.
• The company is obligated to file a registration statement for the resale of the conversion shares within 30 days of the Conversion Share Delivery Date.
• The company must ensure the registration statement is declared effective within 70 days of the Conversion Share Delivery Date.

Key Dates

Keywords

convertible note, financing, secured debt, biopharma, CAR-T therapy, capital raise, intellectual property, equity conversion